Deal Watch: Much Activity Beyond GSK/Novartis/Lilly Pacts And Valeant/Allergan Bid

 
• By Cathy Kelly, John Davis, Lisa LaMotta, and Jessica Merrill

In addition to the mega-deal, Valeant’s latest acquisition gambit and the Pfizer/AstraZeneca rumors, the hectic week saw Celgene pay a huge upfront for a Phase III Crohn’s candidate, Aastrom purchase Sanofi’s regenerative medicine business and The Medicines Company add to its surgical products portfolio.

More from Archive

More from Pink Sheet